Literature DB >> 31778232

Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases.

Zeinab Wehbe1,2, Sara Tucci1.   

Abstract

In the past 15 years the potential of triheptanoin for the treatment of several human diseases in the area of clinical nutrition has grown considerably. Use of this triglyceride of the odd-chain fatty acid heptanoate has been proposed and applied for the treatment of several conditions in which the energy supply from citric acid cycle intermediates or fatty acid degradation are impaired. Neurological diseases due to disturbed glucose metabolism or metabolic diseases associated with impaired β-oxidation of long chain fatty acid may especially take advantage of alternative substrate sources offered by the secondary metabolites of triheptanoin. Epilepsy due to deficiency of the GLUT1 transporter, as well as diseases associated with dysregulation of neuronal signalling, have been treated with triheptanoin supplementation, and very recently the advantages of this oil in long-chain fatty acid oxidation disorders have been reported. The present review summarises the published literature on the metabolism of triheptanoin including clinical reports related to the use of triheptanoin.
© 2019 SSIEM.

Entities:  

Keywords:  anaplerosis; epilepsy and neurodegenerative diseases; metabolic diseases; triheptanoin

Year:  2019        PMID: 31778232     DOI: 10.1002/jimd.12199

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  2 in total

Review 1.  Metabolic Stress and Mitochondrial Dysfunction in Ataxia-Telangiectasia.

Authors:  Goutham Narayanan Subramanian; Abrey Jie Yeo; Magtouf Hnaidi Gatei; David John Coman; Martin Francis Lavin
Journal:  Antioxidants (Basel)       Date:  2022-03-28

Review 2.  Triheptanoin: First Approval.

Authors:  Matt Shirley
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.